Complementary Immunometabolic Effects of Exercise and PPARβ/δ Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice.
Animals
Diet, High-Fat
Energy Metabolism
/ drug effects
Female
Glucose
/ metabolism
Insulin Resistance
Lipid Metabolism
Lymphocyte Count
Mice
Mice, Obese
Muscle, Skeletal
/ drug effects
Obesity
/ etiology
PPAR delta
/ agonists
PPAR-beta
/ agonists
Physical Conditioning, Animal
T-Lymphocytes, Regulatory
/ drug effects
Thiazoles
/ pharmacology
Weight Loss
inflammation
peroxisome proliferator-activated receptor
regulatory T cells
training
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Oct 2019
19 Oct 2019
Historique:
received:
18
09
2019
revised:
14
10
2019
accepted:
17
10
2019
entrez:
23
10
2019
pubmed:
23
10
2019
medline:
28
2
2020
Statut:
epublish
Résumé
Regular aerobic exercise, independently of weight loss, improves metabolic and anti-inflammatory states, and can be regarded as beneficial in counteracting obesity-induced low-grade inflammation. However, it is still unknown how exercise alters immunometabolism in a context of dietary changes. Agonists of the Peroxisome Proliferator Activated-Receptor beta/delta (PPARβ/δ) have been studied this last decade as "exercise-mimetics", which are potential therapies for metabolic diseases. In this study, we address the question of whether PPARβ/δ agonist treatment would improve the immunometabolic changes induced by exercise in diet-induced obese female mice, having switched from a high fat diet to a normal diet. 24 mice were assigned to groups according to an 8-week exercise training program and/or an 8-week treatment with 3 mg/kg/day of GW0742, a PPARβ/δ agonist. Our results show metabolic changes of peripheral lymphoid tissues with PPARβ/δ agonist (increase in fatty acid oxidation gene expression) or exercise (increase in AMPK activity) and a potentiating effect of the combination of both on the percentage of anti-inflammatory Foxp3+ T cells. Those effects are associated with a decreased visceral adipose tissue mass and skeletal muscle inflammation (TNF-α, Il-6, Il-1β mRNA level), an increase in skeletal muscle oxidative capacities (citrate synthase activity, endurance capacity), and insulin sensitivity. We conclude that a therapeutic approach targeting the PPARβ/δ pathway would improve obesity treatment.
Identifiants
pubmed: 31635041
pii: ijms20205182
doi: 10.3390/ijms20205182
pmc: PMC6829333
pii:
doi:
Substances chimiques
PPAR delta
0
PPAR-beta
0
Thiazoles
0
(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid
4PZK9FJC4Z
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Française de Lutte contre le Dopage
ID : AFLD_2017-00016
Références
Physiol Rev. 2014 Jul;94(3):795-858
pubmed: 24987006
Eur J Cardiovasc Prev Rehabil. 2007 Dec;14(6):837-43
pubmed: 18043308
JCI Insight. 2017 Feb 9;2(3):e89160
pubmed: 28194435
J Nutr Biochem. 2019 Jul;69:44-52
pubmed: 31048208
Obes Rev. 2009 Mar;10(2):154-67
pubmed: 19021872
J Clin Invest. 2015 Jan;125(1):194-207
pubmed: 25437876
Science. 2003 Feb 14;299(5609):1057-61
pubmed: 12522256
Obes Rev. 2016 Dec;17(12):1226-1244
pubmed: 27743411
Nat Med. 2014 Nov;20(11):1327-33
pubmed: 25282359
J Immunol. 2014 Jan 15;192(2):623-9
pubmed: 24323581
Am J Physiol Endocrinol Metab. 2008 Sep;295(3):E586-94
pubmed: 18577694
Front Immunol. 2019 Feb 04;10:115
pubmed: 30778354
Front Immunol. 2017 Nov 27;8:1632
pubmed: 29230216
Eur J Clin Invest. 2017 Aug;47(8):600-611
pubmed: 28722106
J Immunol. 2018 Oct 15;201(8):2215-2219
pubmed: 30209190
Immunology. 2010 Aug;130(4):572-88
pubmed: 20406305
Obes Rev. 2015 Feb;16(2):171-86
pubmed: 25494712
FASEB J. 2016 Mar;30(3):1287-99
pubmed: 26655383
Cell Metab. 2017 Jun 6;25(6):1282-1293.e7
pubmed: 28416194
Sci Rep. 2016 Sep 29;6:34317
pubmed: 27680392
Diabetes. 2018 Mar;67(3):360-371
pubmed: 29233935
Biol Sex Differ. 2019 Apr 3;10(1):16
pubmed: 30944030
Cell. 2008 Aug 8;134(3):405-15
pubmed: 18674809
Am J Physiol Endocrinol Metab. 2013 May 1;304(9):E964-76
pubmed: 23482446
Diabetes. 2013 Apr;62(4):1032-5
pubmed: 23520282
Am J Reprod Immunol. 2018 Mar;79(3):
pubmed: 29315988
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7815-20
pubmed: 18509063
Nat Immunol. 2016 May 19;17(6):618-25
pubmed: 27196520
Int J Mol Sci. 2018 May 25;19(6):null
pubmed: 29799467
J Clin Invest. 2012 Nov;122(11):4105-17
pubmed: 23093780
Immunity. 2017 Sep 19;47(3):406-420
pubmed: 28930657
Exp Clin Endocrinol Diabetes. 2018 Feb;126(2):96-101
pubmed: 28954308
Nat Cell Biol. 2011 Sep 02;13(9):1016-23
pubmed: 21892142
Brain Behav Immun. 2009 Jul;23(5):643-8
pubmed: 19133324
J Immunol. 2011 Mar 15;186(6):3299-303
pubmed: 21317389
Nature. 2017 Feb 8;542(7640):177-185
pubmed: 28179656
Immunity. 2015 Jan 20;42(1):41-54
pubmed: 25607458
Diabetes. 2018 Feb;67(2):169-179
pubmed: 29358486
Mol Endocrinol. 2011 Sep;25(9):1487-98
pubmed: 21798999
Eur J Appl Physiol. 2013 Jul;113(7):1839-48
pubmed: 23435500
Lancet Public Health. 2017 May 19;2(6):e277-e285
pubmed: 28626830
Int J Obes (Lond). 2015 Nov;39(11):1607-18
pubmed: 26041698
FASEB J. 2003 Dec;17(15):2299-301
pubmed: 14525942
J Allergy Clin Immunol. 2016 May;137(5):1607-1610.e8
pubmed: 26774657
Physiol Genomics. 2008 Feb 19;32(3):360-9
pubmed: 18042831
Am J Physiol Endocrinol Metab. 2012 Jun 15;302(12):E1541-9
pubmed: 22496344
Eur J Immunol. 2017 Feb;47(2):225-235
pubmed: 28054344
Nat Rev Immunol. 2011 Aug 05;11(9):607-15
pubmed: 21818123
Diabetes. 2007 Aug;56(8):2085-92
pubmed: 17519422
Nat Immunol. 2008 Jun;9(6):632-40
pubmed: 18438410
Physiol Behav. 2017 Jul 1;176:174-182
pubmed: 28284880
Biochimie. 2017 May;136:33-41
pubmed: 27939528
Immunity. 2015 Sep 15;43(3):421-34
pubmed: 26377896